Dr. Bill W. Colston Jr., Ph.D. serves as Independent Director of the Company. Colston is President of iCarbonX and has more than 30 years of experience across a range of innovative life science and technology ventures. Colston has served as President of personal health company iCarbonX since March 2019. He joined iCarbonX as Chief Operating Officer in April 2018, following its acquisition of his prior company, and is a member of its Board of Directors. Previously, he was a co-founder and Chief Executive Officer of HealthTell Inc., a company focused on developing next-generation tests that broadly characterize the immune system. He was also scientific founder and CEO of QuantaLife Inc., which developed a genetic analysis system that is now marketed internationally. Colston began his career at Lawrence Livermore National Laboratory, where he served in various senior leadership roles over a nearly 20-year career and helped build the first civilian biodefense program in the United States. Colston is also a board member of companies including Purigen Biosystems and RubrYc Therapeutics. He holds a PhD in biomedical engineering from the University of California, Davis.
As the Independent Director of Standard BioTools Inc, the total compensation of Bill Colston at Standard BioTools Inc is $131,309. There are 12 executives at Standard BioTools Inc getting paid more, with Stephen Linthwaite having the highest compensation of $3,713,060.
Bill Colston is 52, he's been the Independent Director of Standard BioTools Inc since 2019. There are 6 older and 7 younger executives at Standard BioTools Inc. The oldest executive at Standard BioTools Inc is Vikram Jog, 65, who is the Chief Financial Officer.
Bill's mailing address filed with the SEC is C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, STE 2000, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 14 years, insiders at Standard BioTools Inc have traded over $29,087,682 worth of Standard BioTools Inc stock and bought 4,143,303 units worth $24,269,186 . The most active insiders traders include Easterly Partners Llcle Par..., Capital Strategies, L.P.Lev... и Samuel D Colella. On average, Standard BioTools Inc executives and independent directors trade stock every 9 days with the average trade being worth of $72,208. The most recent stock trade was executed by Nicolas Barthelemy on 1 April 2022, trading 20,993 units of FLDM stock currently worth $78,514.
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all.
Standard BioTools Inc executives and other stock owners filed with the SEC include: